Cargando…
Oral Maintenance Chemotherapy with 6-Mercaptopurine and Methotrexate in Patients with Acute Myeloid Leukemia Ineligible for Transplantation
For decades, maintenance chemotherapy has failed to improve the cure rate or prolong the survival of patients with acute myeloid leukemia (AML), other than those with acute promyelocytic leukemia. Immediately after the first complete remission following consolidation therapy was obtained, oral maint...
Autores principales: | Choi, Yong Won, Jeong, Seong Hyun, Ahn, Mi Sun, Lee, Hyun Woo, Kang, Seok Yun, Choi, Jin-Hyuk, Park, Joon Seong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Academy of Medical Sciences
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4575929/ https://www.ncbi.nlm.nih.gov/pubmed/26425037 http://dx.doi.org/10.3346/jkms.2015.30.10.1416 |
Ejemplares similares
-
Mercaptopurine/Methotrexate Maintenance Therapy of Childhood Acute Lymphoblastic Leukemia: Clinical Facts and Fiction
por: Schmiegelow, Kjeld, et al.
Publicado: (2014) -
Subcutaneous azacitidine maintenance in transplant-ineligible patients with acute myeloid leukemia: a single-center retrospective study
por: Johnson, Natacha, et al.
Publicado: (2023) -
Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy
por: Yamamoto, Kazuhito, et al.
Publicado: (2021) -
Outcomes of bortezomib combination chemotherapies in autologous stem cell transplantation-ineligible patients with AL amyloidosis
por: Hur, Joon Young, et al.
Publicado: (2021) -
Venetoclax and Azacitidine in Chinese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy
por: Xia, Leiming, et al.
Publicado: (2023)